Lampasona, Vito

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Bastard, P., Rosen, L. B., Zhang, Q., Michailidis, E., Hoffmann, H.-H., Zhang, Y., Dorgham, K., Philippot, Q., Rosain, J., Béziat, V., et al. (2020) · Science

interferon and immune responsesSARS-CoV-2 and COVID-19 Research

Cited by 2,662

Identification of tetraspanin-7 as a target of autoantibodies in type 1 diabetes

McLaughlin, K. A., Richardson, C. C., Ravishankar, A., Brigatti, C., Liberati, D., Lampasona, V., Piemonti, L., Morgan, D., Feltbower, R. G., & Christie, M. R. (2016) · Diabetes

Diabetes and associated disordersT-cell and B-cell Immunology

Cited by 113

BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease

Cangi, M. G., Biavasco, R., Cavalli, G., Grassini, G., Dal-Cin, E., Campochiaro, C., Guglielmi, B., Berti, A., Lampasona, V., von Deimling, A., et al. (2015) · Annals of the Rheumatic Diseases

Histiocytic Disorders and TreatmentsSarcoidosis and Beryllium Toxicity Research

Cited by 112

Early development and spreading of autoantibodies to epitopes of IA-2 and their association with progression to type 1 diabetes

Naserke, H. E., Ziegler, A.-G., Lampasona, V., & Bonifacio, E. (1998) · The Journal of Immunology

Diabetes and associated disordersDiabetes Management and Research

Cited by 98

Detection of antibodies directed to the N-terminal region of GAD is dependent on assay format and contributes to differences in the specificity of GAD autoantibody assays for type 1 diabetes

Williams, A. J. K., Lampasona, V., Schlosser, M., Mueller, P. W., Pittman, D. L., Winter, W. E., Akolkar, B., Wyatt, R., Brigatti, C., Krause, S., et al. (2015) · Diabetes

Diabetes and associated disordersDiabetes Management and Research

Cited by 46